On November 25, 2020, Osaka City signed an agreement with Cancer Scan Co., Ltd. and Amgen Co., Ltd. regarding the "Public-Private Partnership Osteoporosis Disease Awareness Project (Disease Awareness Commons)" (hereinafter referred to as the "Tripartite Agreement"). We have been working on countermeasures against osteoporosis, which is one of the major causes that hinder healthy life expectancy.

Osteoporosis is not simply bone aging, but a disease in which bones become fragile and prone to fracture due to abnormal bone metabolism. Fractures caused by osteoporosis are called "vulnerability fractures," and fractures of the spine and thigh bones are especially common, and this is one of the causes that hinders healthy life expectancy. Osteoporosis, which causes these fragility fractures, is a common disease among elderly women, but young people and men also suffer from it. Once a fragility fracture occurs, it is known that the risk of "secondary fracture", which causes a chain reaction of subsequent fractures in a short period of time, is extremely high. The number of osteoporosis patients in Japan is estimated to be about 12.8 million (1 in 3 people over the age of 65), but about 2 million people are receiving treatment because they are asymptomatic. It is said that there is only one.

This tripartite agreement promotes awareness of osteoporosis and encourages people who have not yet started treatment for osteoporosis to receive treatment to prevent secondary fractures despite having experienced a bone fracture. This agreement was concluded with the aim of preventing fragility fractures and extending healthy life expectancy. It has been compiled and will be published.

This report has been prepared by Cancer Scan Co., Ltd. based on a "Tripartite Agreement".

We hope that this project will be of assistance in projects aimed at extending healthy life expectancy. Osaka City will continue to explore activities aimed at extending the healthy life expectancy of its citizens.

Document creator

Cancer Scan Co., Ltd.

〇 Cancer Scan Co., Ltd. (1-3-8 Nishi-Gotanda, Shinagawa-ku, Tokyo Gotanda PLACE 2F)

Support for health programs in more than 700 municipalities (as of 2022)
Responsible for the production of the Handbook for Improving Examination Rates issued by the Ministry of Health, Labor and Welfare to municipalities (2015, 2019)
Received the Best Nudge Award from the Ministry of the Environment and the Society of Behavioral Economics (2018)
Implemented Japan's first SIB (Socia Impact Bond) project at the national health insurance company (2017)

〇 Amgen Co., Ltd. (Midtown Tower, 9-7-1 Akasaka, Minato-ku, Tokyo)

Amgen K.K. is the Japanese subsidiary of Amgen Inc., one of the world's largest independent biotechnology companies. In October 2013, we started business as Amgen Astellas BioPharma, a joint venture with Astellas Pharma Inc., and on April 1, 2020, we changed our trade name to become a wholly owned subsidiary of Amgen. At Amgen K.K., we focus on areas of high unmet medical need, including cardiovascular disease, cancer, bone disease, inflammation/immune disease, and neurological disease. Under the mission of “To serve patients – do everything we can do now for patients”, we are engaged in activities from clinical development to sales.